BioSpace News Archive

TrialSpark announced a new partnership with global pharmaceutical company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently.

Connect Biopharma Holdings Limited announced topline results for the primary analysis population of the pivotal trial of the Company’s lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis in China.

Alafair Biosciences, Inc., a commercial-stage medical device company, announced that sales of its flagship product, VersaWrap®, have now exceeded 5000 units since commercial launch.

Quantgene, a Santa Monica, California, and Berlin, Germany-based biotechnology, cloud and artificial intelligence company, will host a delegation of healthcare executives and scientific leaders from Baden-Württemberg at its headquarters on October 5.

ImpediMed Limited is pleased to announce the signing of a Global Strategic Commercial Partnership and pilot program with GenesisCare.

RSIP Vision, a leader in driving innovation for medical imaging through advanced AI and computer vision solutions, announces a new tool for 3D reconstruction of the ureter.

Lyme disease is the fastest-growing vector-borne disease in the United States, and its increased prevalence is challenging the scientific community to look for new ways to diagnose and treat this worrisome infection.

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company has now completed cGMP manufacturing of a multi-kilogram lot of cepharanthine-2HCl for use in the final drug product production of PD-001, its patented, orally bioavailable version of cepharanthine.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased to announce that the Company has commenced discussions with pharmaceutical companies to explore potential clinical trial financing alternatives for its lead product ACP-01 (the “Clinical Trial Financing Alternatives”)

Saluda Medical Pty Limited, a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies, announced the appointment of Laureen DeBuono to its board of directors.